Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.
Female
Gene Expression Regulation, Neoplastic
/ radiation effects
Humans
Male
Neoplasm Proteins
/ genetics
Neuroendocrine Tumors
/ genetics
Pancreatic Neoplasms
/ genetics
Polymorphism, Single Nucleotide
/ genetics
Radioisotopes
/ therapeutic use
Receptors, Formyl Peptide
/ therapeutic use
Transcriptome
/ radiation effects
Journal
The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
26
02
2020
revised:
07
05
2020
accepted:
15
05
2020
pubmed:
6
9
2020
medline:
24
9
2020
entrez:
5
9
2020
Statut:
ppublish
Résumé
Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocrine tumours (NETs). Some of the key challenges in its use are the prediction of efficacy and toxicity, patient selection, and response optimisation. In this Review, we assess current knowledge on the molecular profile of NETs and the strategies and tools used to predict, monitor, and assess the toxicity of PRRT. The few mutations in tumour genes that can be evaluated (eg, ATM and DAXX) are limited to pancreatic NETs and are most likely not informative. Assays that are transcriptomic or based on genes are effective in the prediction of radiotherapy response in other cancers. A blood-based assay for eight genes (the PRRT prediction quotient [PPQ]) has an overall accuracy of 95% for predicting responses to PRRT in NETs. No molecular markers exist that can predict the toxicity of PRRT. Candidate molecular targets include seven single nucleotide polymorphisms (SNPs) that are susceptible to radiation. Transcriptomic evaluations of blood and a combination of gene expression and specific SNPs, assessed by machine learning with algorithms that are tumour-specific, might yield molecular tools to enhance the efficacy and safety of PRRT.
Identifiants
pubmed: 32888472
pii: S1470-2045(20)30323-5
doi: 10.1016/S1470-2045(20)30323-5
pmc: PMC8385643
mid: NIHMS1718583
pii:
doi:
Substances chimiques
Neoplasm Proteins
0
Radioisotopes
0
Receptors, Formyl Peptide
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e431-e443Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Endocr Relat Cancer. 2017 Feb;24(2):L21-L25
pubmed: 28049633
Neuroendocrinology. 2020;110(7-8):662-670
pubmed: 31597134
Nat Med. 2019 Aug;25(8):1260-1265
pubmed: 31263286
Subcell Biochem. 2014;85:133-59
pubmed: 25201193
Thorax. 1988 Mar;43(3):195-9
pubmed: 3406904
J Natl Cancer Inst. 2020 Feb 1;112(2):179-190
pubmed: 31095341
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):895-906
pubmed: 31838581
Mol Imaging Biol. 2017 Jun;19(3):437-445
pubmed: 27743210
Mod Pathol. 2013 May;26(5):685-96
pubmed: 23328977
Endocr Relat Cancer. 2019 Jan 1;26(4):391-403
pubmed: 30667365
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6
pubmed: 26611427
J Pathol. 2017 Mar;241(4):488-500
pubmed: 27873319
J Clin Oncol. 2010 Jan 10;28(2):245-55
pubmed: 19917848
BMC Genomics. 2012 Jul 30;13:348
pubmed: 22846430
Endocr Relat Cancer. 2017 Aug;24(8):427-443
pubmed: 28634180
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499
pubmed: 27704193
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Sci Transl Med. 2013 Oct 16;5(207):207ra142
pubmed: 24132637
J Nucl Med. 2010 Sep;51(9):1349-56
pubmed: 20720050
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Endocr Relat Cancer. 2006 Jun;13(2):541-58
pubmed: 16728581
Nat Rev Clin Oncol. 2017 Apr;14(4):235-246
pubmed: 27922044
Acta Oncol. 1989;28(2):193-7
pubmed: 2544211
Clin Cancer Res. 2012 Sep 15;18(18):5134-43
pubmed: 22832933
Mol Imaging Biol. 2015 Jun;17(3):313-8
pubmed: 25319765
J Thorac Oncol. 2015 Apr;10(4):629-37
pubmed: 25590604
Radiother Oncol. 2019 Dec;141:108-115
pubmed: 31542317
Oncotarget. 2017 Jan 24;8(4):7039-7049
pubmed: 27705948
J Thorac Oncol. 2018 Jun;13(6):752-766
pubmed: 29454048
Nat Commun. 2019 Aug 20;10(1):3407
pubmed: 31431620
Nature. 1988 Dec 8;336(6199):577-80
pubmed: 3200306
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
Neuroendocrinology. 2020;110(5):322-327
pubmed: 31694034
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
BMC Genomics. 2014 Jul 15;15:595
pubmed: 25023465
Expert Rev Mol Diagn. 2019 Apr;19(4):281-297
pubmed: 30900485
Mol Cancer Res. 2018 Oct;16(10):1523-1529
pubmed: 29903771
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46
pubmed: 25808630
World J Nucl Med. 2017 Apr-Jun;16(2):126-132
pubmed: 28553179
Radiother Oncol. 2016 Dec;121(3):431-439
pubmed: 27443449
Nucl Med Commun. 2016 Oct;37(10):1030-7
pubmed: 27243215
BMC Med Genomics. 2014 Jul 12;7:43
pubmed: 25017500
Transl Oncol. 2018 Apr;11(2):193-204
pubmed: 29331677
Acta Oncol. 2015;54(9):1665-8
pubmed: 26268305
Gastroenterology. 2015 Jul;149(1):67-78
pubmed: 25865046
Clin Cancer Res. 2016 Jan 1;22(1):250-8
pubmed: 26169971
Expert Rev Mol Diagn. 2015;15(8):971-4
pubmed: 26134385
J Nucl Med. 2014 Feb;55(2):183-90
pubmed: 24434296
Clin Cancer Res. 2010 Feb 1;16(3):978-85
pubmed: 20103666
Oncol Lett. 2019 Jun;17(6):5377-5388
pubmed: 31186755
Onco Targets Ther. 2018 Jul 06;11:3901-3918
pubmed: 30013370
Radiat Res. 2016 Sep;186(3):235-44
pubmed: 27556353
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
J Endocrinol. 2018 Mar;236(3):R161-R167
pubmed: 29321190
Clin Ophthalmol. 2014 Dec 03;8:2449-60
pubmed: 25587217
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Oncotarget. 2015 Oct 27;6(33):34414-22
pubmed: 26451615
Clin Cancer Res. 2018 May 1;24(9):2182-2193
pubmed: 29440175
J Clin Endocrinol Metab. 2019 Feb 1;104(2):285-292
pubmed: 30219888
Oncotarget. 2018 Sep 4;9(69):33059
pubmed: 30237849
Oncogene. 2017 Mar;36(10):1384-1393
pubmed: 27775076
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):497-505
pubmed: 19735874
Cancer Discov. 2014 Feb;4(2):155-65
pubmed: 24441285
Nuklearmedizin. 2013;52(5):170-7
pubmed: 23963021
Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83
pubmed: 28533939
Endocr Relat Cancer. 2008 Mar;15(1):243-56
pubmed: 18310291
Am J Pathol. 1998 Oct;153(4):1089-98
pubmed: 9777940
Semin Radiat Oncol. 2010 Oct;20(4):232-40
pubmed: 20832015
Dis Colon Rectum. 1991 Jan;34(1):31-6
pubmed: 1991417
Endocr Relat Cancer. 2015 Aug;22(4):561-75
pubmed: 26037279
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96
pubmed: 19735873
J Clin Oncol. 2006 Oct 10;24(29):4677-84
pubmed: 16966691
Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851
pubmed: 26596723
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807
J Clin Invest. 2013 Jun;123(6):2502-8
pubmed: 23676460
Virchows Arch. 2018 Dec;473(6):709-717
pubmed: 30219970
J Nucl Med. 2020 Jul;61(7):1014-1020
pubmed: 31806775
Nat Genet. 2013 Dec;45(12):1483-6
pubmed: 24185511
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195